Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease

Table 5 Statistical association between PsAID-12 and MDA

Domains PsAID	Non-MDA	MDA	VLDA	p*
Domains PsAID	Median (P25-P75)	Median (P25-P75)	Median (P25-P75)	p*
Pains	6 (3-8)^c	3 (1-5)^b	0 (0-0.5)^a	< 0.001
Fatigue/Tiredness	5 (3-7.8)^b	2 (1.5-4.5)^a	0 (0-1.5)^a	< 0.001
Skin Problems	4 (1.3-6.8)^b	1 (0-2.5)^a	0 (0-3)^a	< 0.001
Work and/or leisure activity	5 (2-8)^b	2 (0-4)^a	0 (0-0)^a	< 0.001
Physical Ability	6 (3-8)^b	3 (1-5)^a	0.5 (0-1)^a	< 0.001
Discomfort	5 (3-8)^b	2 (0.5-4)^a	0 (0-0.3)^a	< 0.001
Sleep disturbance	3 (0.3-7)^b	1 (0-3)^ab	0 (0-0)^a	< 0.001
Dealing with the disease	4.5 (2-6)^b	2 (0-3)^a	0 (0-1)^a	< 0.001
Anxiety/Fear/Uncertainty	5 (2.3-8)^b	2 (0-4.5)^a	0 (0-0.3)^a	< 0.001
Embarrassment and/or shame	2 (0-5)^b	0 (0-1.5)^ab	0 (0-0)^a	< 0.001
Social Participation	2 (0-5.8)^b	0 (0-1.5)^a	0 (0-0)^a	< 0.001
Depression	2.5 (0-6)^b	1 (0-2)^ab	0 (0-0)^a	< 0.001
Total score	4.7 (3.0-6.4)^c	2.2 (1.4-3.6)^b	0.5 (0.2-0.9)^a	< 0.001
Total PsAID ≤4 – n (%)	44 (42.3)^a	18 (85.7)^b	14 (100)^b	< 0.001

PsAID Psoriatic Arthritis Impact of Disease, MDA Minimal Disease Activity, VLDA Very Low Disease Activity
^*Kruskal-Wallis test; a, b, c Equal letters don’t differ by the Dunn test or residuals adjusted at 5% significance

ISSN: 2523-3106